A selected ion monitoring method for quantifying simvastatin and its acid form in human plasma, using the ferroceneboronate derivative

Biomed Environ Mass Spectrom. 1990 Sep;19(9):577-81. doi: 10.1002/bms.1200190910.

Abstract

Simvastatin, a pro-drug lactone, forms the open carboxylic acid as a major metabolite that inhibits the activity of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Simvastatin and the acid in plasma were quantified by a gas chromatography/mass spectrometry/selected ion monitoring (GC/MS/SIM) method. These drugs were separated by solid-phase extraction and independently converted into a 1,3-diol-type compound. This compound reacted with ferroceneboronic acid to yield the cyclic boronate that gave satisfactory mass spectra for GC/MS/SIM measurements. The serum was dominated by the molecular ion appearing as the base peak, thereby leading to a sensitive and selective assay. The calibration curves for simvastatin and the acid were linear in their concentration range of 0.1-10 ng ml-1, where the values of coefficient of variation for both drugs were below 8%, except for the value of 11% for simvastatin at a concentration of 0.1 ng ml-1. The quantification limit for both drugs was 0.1 ng ml-1 on the basis of a signal-to-noise ratio of 4:1.

MeSH terms

  • Ferrous Compounds
  • Gas Chromatography-Mass Spectrometry
  • Humans
  • Lovastatin / analogs & derivatives*
  • Lovastatin / blood
  • Metallocenes
  • Methylation
  • Organometallic Compounds
  • Simvastatin

Substances

  • Ferrous Compounds
  • Metallocenes
  • Organometallic Compounds
  • Lovastatin
  • Simvastatin
  • ferrocene